Understanding the Symptoms of Depression

Depression is a mental health condition that affects millions of people worldwide. It is characterized by a persistent feeling of sadness, hopelessness, and despair. The three core symptoms of depression are depressed mood, anhedonia, and anergia. To receive a diagnosis of depression, a person must have at least two of these core symptoms, as well as other non-core symptoms such as reduced concentration, disturbed sleep, and diminished appetite.

While disturbed sleep and diminished appetite are common symptoms of depression, they are not considered core symptoms. On the other hand, overactivity and grandiose ideation are not typical symptoms of depression, as patients with depression usually have reduced activity and negative thoughts.

Reduced self-esteem and self-confidence are also common in depression, but they are not considered core symptoms. In severe cases of depression, patients may experience catatonia and paranoid ideation, as well as other psychotic symptoms such as hallucinations and delusions.

It is important to recognize the symptoms of depression and seek help if you or someone you know is struggling with this condition. With proper treatment, including therapy and medication, many people with depression can recover and lead fulfilling lives.

Understanding the Different Sections of the Mental Health Act (2007)

The Mental Health Act (2007) provides a legal framework for patients with confirmed or suspected mental disorders that pose a risk to themselves or the public. The Act outlines specific guidelines for detention, treatment, and the individuals authorized to use its powers. Here are some of the key sections of the Mental Health Act:

Section 5(2): This section allows for the temporary detention of a patient already in the hospital for up to 72 hours, after which a full Mental Health Act assessment must be conducted. A doctor who is fully registered (FY2 or above) can use this section to detain a patient.

Section 3: This section is used for admission for treatment for up to 6 months, with the exact mental disorder being treated stated on the application. It can be renewed for a further six months if required, and the patient has the right to appeal.

Section 2: This section allows for compulsory admission for assessment of presumed mental disorder. The section lasts for 28 days and must be signed by two doctors, one of whom is approved under Section 12(2), usually a consultant psychiatrist, and another doctor who knows the patient in a professional capacity, usually their GP.

Section 5(4): This section can be used by psychiatric nursing staff to detain a patient for up to 6 hours while arranging review by appropriate medical personnel for further assessment and either conversion to a Section 5(2). If this time elapses, there is no legal right for the nursing staff to detain the patient. In this scenario, the nursing staff are unavailable to assess the patient.

Section 7: This section is an application for guardianship. It is used for patients in the community where an approved mental health practitioner (AMHP), usually a social worker, requests compulsory treatment requiring the patient to live in a specified location, attend specific locations for treatment, and allow access for authorized persons.

Sertraline is the recommended first-line medication for generalised anxiety disorder (GAD). This is because the patient has already tried non-pharmacological measures with little benefit. Diazepam, a benzodiazepine, is not recommended due to the risk of tolerance and addiction. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is not first-line but may be considered if the patient does not respond to sertraline. Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), is not generally recommended for GAD.

Anxiety is a common disorder that can manifest in various ways. According to NICE, the primary feature is excessive worry about multiple events associated with heightened tension. It is crucial to consider potential physical causes when diagnosing anxiety disorders, such as hyperthyroidism, cardiac disease, and medication-induced anxiety. Medications that may trigger anxiety include salbutamol, theophylline, corticosteroids, antidepressants, and caffeine.

NICE recommends a step-wise approach for managing generalised anxiety disorder (GAD). This includes education about GAD and active monitoring, low-intensity psychological interventions, high-intensity psychological interventions or drug treatment, and highly specialist input. Sertraline is the first-line SSRI for drug treatment, and if it is ineffective, an alternative SSRI or a serotonin-noradrenaline reuptake inhibitor (SNRI) such as duloxetine or venlafaxine may be offered. If the patient cannot tolerate SSRIs or SNRIs, pregabalin may be considered. For patients under 30 years old, NICE recommends warning them of the increased risk of suicidal thinking and self-harm and weekly follow-up for the first month.

The management of panic disorder also follows a stepwise approach, including recognition and diagnosis, treatment in primary care, review and consideration of alternative treatments, review and referral to specialist mental health services, and care in specialist mental health services. NICE recommends either cognitive behavioural therapy or drug treatment in primary care. SSRIs are the first-line drug treatment, and if contraindicated or no response after 12 weeks, imipramine or clomipramine should be offered.

Biochemical and Haematological Abnormalities in Anorexia Nervosa

Anorexia nervosa is a condition that can lead to a wide range of biochemical and haematological abnormalities. These abnormalities include hypokalaemia and hypochloraemic alkalosis, which are caused by vomiting and/or diuretic/laxative abuse. Additionally, hypercholesterolaemia is often present in individuals with anorexia nervosa, although the mechanism behind this is not yet fully understood.

When it comes to haematological abnormalities, the erythrocyte sedimentation rate (ESR) is typically normal or reduced in individuals with anorexia nervosa. Furthermore, the white cell count may be low. These abnormalities can have serious consequences for individuals with anorexia nervosa, and it is important for healthcare professionals to be aware of them in order to provide appropriate treatment and care.

Emergency Detention under Section 5(2) of the Mental Health Act

Section 5(2) of the Mental Health Act provides a legal provision for emergency detention of patients suspected of having a psychiatric cause for their illness. This section can be invoked by registered medical practitioners who are F2 and above. Once invoked, the patient can be detained for up to 72 hours while awaiting a Mental Health Act assessment. This provision is crucial in situations where a patient’s mental health poses a risk to themselves or others, and urgent intervention is required. The 72-hour period allows for a thorough assessment of the patient’s mental health status and the development of an appropriate care plan. It is important to note that the use of this section should be in line with the principles of the Mental Health Act, which prioritizes the least restrictive option for patients.

Combining SSRIs and MAOIs is not recommended due to the potential danger of developing serotonin syndrome.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

Peripheral visual impairment is a risk factor for Charles-Bonnet syndrome, which is a condition characterized by visual hallucinations in individuals with eye disease. The most frequent hallucinations include faces, children, and wild animals. This syndrome is more common in older individuals, without significant difference in occurrence between males and females, and no known increased risk associated with family history.

Understanding Charles-Bonnet Syndrome

Charles-Bonnet syndrome (CBS) is a condition characterized by complex hallucinations, usually visual or auditory, that occur in clear consciousness. These hallucinations persist or recur and are often experienced by individuals with visual impairment, although this is not a mandatory requirement for diagnosis. People with CBS maintain their insight and do not exhibit any other significant neuropsychiatric disturbance. The risk factors for CBS include advanced age, peripheral visual impairment, social isolation, sensory deprivation, and early cognitive impairment. The syndrome is equally distributed between sexes and does not show any familial predisposition. The most common ophthalmological conditions associated with CBS are age-related macular degeneration, glaucoma, and cataract.

Well-formed complex visual hallucinations are experienced by 10-30% of individuals with severe visual impairment. The prevalence of CBS in visually impaired people is estimated to be between 11 and 15%. However, around a third of people with CBS find the hallucinations unpleasant or disturbing. A large study published in the British Journal of Ophthalmology found that 88% of people had CBS for two years or more, and only 25% experienced resolution at nine years. Therefore, CBS is not generally a transient experience.

Electroconvulsive therapy (ECT) should only be considered as a treatment option for individuals with severe major depressive disorder that is potentially life-threatening, and where other treatments have been ineffective. It is also recommended for those experiencing catatonia or a prolonged/severe manic episode.

Electroconvulsive therapy (ECT) is a viable treatment option for patients who suffer from severe depression that does not respond to medication, such as catatonia, or those who experience psychotic symptoms. The only absolute contraindication for ECT is when a patient has raised intracranial pressure.

Short-term side effects of ECT include headaches, nausea, short-term memory impairment, memory loss of events prior to the therapy, and cardiac arrhythmia. However, these side effects are typically temporary and resolve quickly.

Long-term side effects of ECT are less common, but some patients have reported impaired memory. It is important to note that the benefits of ECT often outweigh the potential risks, and it can be a life-changing treatment for those who have not found relief from other forms of therapy.

Knowing the side effects of ECT is crucial as it is a treatment that is often viewed with apprehension by the public. ECT is typically used to treat depression that is resistant to other treatments, as well as severe mania and catatonic schizophrenia. While it was once a feared treatment due to its use of high strengths and lack of anesthesia, it is now considered to be a relatively safe intervention. Short-term side effects of ECT include headaches, nausea, memory problems, and cardiac arrhythmias. There are few long-term effects, although some patients may experience long-term memory issues. ECT is used to treat mania and is being studied as a potential treatment for Parkinson’s disease. It induces a generalized seizure but is not associated with epilepsy or glaucoma.

Electroconvulsive therapy (ECT) is a viable treatment option for patients who suffer from severe depression that does not respond to medication, such as catatonia, or those who experience psychotic symptoms. The only absolute contraindication for ECT is when a patient has raised intracranial pressure.

Short-term side effects of ECT include headaches, nausea, short-term memory impairment, memory loss of events prior to the therapy, and cardiac arrhythmia. However, these side effects are typically temporary and resolve quickly.

Long-term side effects of ECT are less common, but some patients have reported impaired memory. It is important to note that the benefits of ECT often outweigh the potential risks, and it can be a life-changing treatment for those who have not found relief from other forms of therapy.

– Circumstantiality: vague speech that wanders off topic before returning to answer the question
– Clanging: using words that sound similar instead of their meaning
– Echolalia: repeating what the examiner says
– Neologism: creating new words
– Perseveration: repeating a word or activity too much